Related by context. All words. (Click for frequent words.) 76 Clinical Trial Results 75 Prolongs Survival 75 Monoclonal Antibody 75 Kinase Inhibitor 74 Antiviral Activity 74 Drug Candidate 74 Antiviral Therapy 74 Novel Oral 74 Antimicrobial Activity 74 Anti Tumor 74 Novel Antibiotic 74 Oritavancin 74 Gram Positive 74 Antitumor Activity 74 Immune Responses 73 Anti Tumor Activity 73 Antitumor 73 Vaccine Adjuvant 73 Study Evaluating 73 Chronic Hepatitis C 73 Immunogenicity 73 Phase 2b Clinical Trial 73 Oral Fingolimod 72 Hepatitis B Virus 72 Previously Treated 72 Pooled Analysis 72 Completes Patient Enrollment 72 Preclinical Study 72 Protease Inhibitor 72 Potent Antiviral Activity 72 Virus Infection 72 Presents Preclinical Data 72 Drug Resistant 72 Combination Therapy 72 Tyrosine Kinase Inhibitor 72 Preclinical Data 72 Drug Shows Promise 72 sunitinib Sutent ® 72 Demonstrates Potent 71 Antibacterials 71 Receives Orphan Drug Designation 71 Epidermal Growth Factor Receptor 71 Phospholipase A2 71 Inflammatory Arthritis 71 Vaccine Candidate 71 Shows Promising 71 Investigational Compound 71 Fungal Infections 71 Unfractionated Heparin 71 Anticancer Activity 71 Complicated Skin 71 Systemic Delivery 71 Anticancer Drugs 71 Pharmacokinetic Study 71 Nucleoside 71 Polymerase Inhibitor 71 Recombinant Human 71 Phase 2a Clinical Trial 71 Chemokine Receptor 71 Unresectable 71 Tezampanel 71 Meets Primary Endpoint 71 Aptamer 71 Presents Positive 71 Human Monoclonal Antibodies 71 Hsp# Inhibitor 71 First Patient Dosed 71 Infected Patients 71 Antifungal 71 Randomized Phase 70 J Clin 70 Inhibits 70 Demonstrates Efficacy 70 Dendritic Cells 70 Crit Rev 70 Human Monoclonal Antibody 70 Phase 2b Trial 70 Oncolytic 70 Meta Analysis 70 Nilotinib 70 IND Application 70 Therapeutic Vaccine 70 Kinase Inhibitors 70 Treating Chronic 70 Attenuates 70 Cancer Res 70 Placebo Controlled Trial 70 Abstract Number 70 Influenza Virus 70 Mouse Model 70 Phase IIb Trial 70 Files IND 70 Advanced Melanoma 70 J Allergy Clin 70 Chronic Lymphocytic Leukemia 70 Small Molecule 70 RNAi Therapeutic 70 Well Tolerated 70 Present Preclinical Data 70 HDAC Inhibitor 70 Novel Inhibitor 70 Shows Promise Against 70 HCV Protease Inhibitor 70 Invasive Fungal Infections 70 Initiates Clinical Trial 70 Myelodysplastic Syndromes 70 Seasonal Influenza Vaccine 69 Cancer Vaccines 69 Phase 2a Trial 69 Linezolid 69 Low Dose 69 Nat Clin Pract 69 Orally Active 69 Interferon Gamma 69 Histone Deacetylase 69 Controlled Trial 69 Cytotoxicity 69 Interferon Beta 69 Anthracycline 69 Anticancer Drug 69 Rotavirus Vaccine 69 Lymphoid 69 Monoclonal Antibodies 69 Dose Ranging Study 69 BAL# [001] 69 Single Dose 69 Phase 2b Study 69 Patients Treated With 69 Antigen Specific 69 Lung Infections 69 Factor Receptor 69 Presents Preclinical 69 Preclinical Models 69 Metastatic Melanoma 69 Investigational Drug 69 Oral Insulin 69 II Clinical Trial 69 Initiate Phase 69 Protease Inhibitors 69 Tigecycline 69 Relapsed Refractory 69 Protein Expression 69 Trial Evaluating 69 Transdermal Patch 69 Combination REOLYSIN R 69 Hepatocellular Carcinoma 69 Clinical Isolates 69 Isavuconazole 69 Initiates Phase II 69 Completes Enrollment 69 Pharmacokinetics PK 69 Novel Therapeutic 69 Effectively Treats 69 Randomized Clinical Trials 69 Bosutinib 69 Double Blind Placebo 69 Submits NDA 69 Clinical Outcome 69 Nitazoxanide 69 Adjuvant Treatment 69 Advanced Renal Cell 69 Treatment Naïve 69 Therapeutic Vaccines 69 Mimetics 69 Cancer Stem Cells 69 Thiovir 69 Adenoviral 69 Hormone Refractory Prostate Cancer 69 Novel Mechanism 69 Potent Anti 69 Phase III Clinical Trial 68 Monoclonal 68 Relapsing Multiple Sclerosis 68 Renal Cell Carcinoma 68 HER2 Positive 68 Mucosal 68 Breast Cancer Cells 68 Oral Presentation 68 Inflammatory Diseases 68 Chronic Hepatitis B 68 FDA Clears 68 JAK Inhibitor 68 Demonstrates Statistically Significant 68 Cardiotoxicity 68 Previously Untreated 68 Adjuvant Chemotherapy 68 Plus Ribavirin 68 See CLINICAL PHARMACOLOGY 68 Oncogene 68 Topical Treatment 68 Polymorphisms 68 Androgen Receptor 68 Protease 68 Vaccine Adjuvants 68 Sirolimus Eluting Stent 68 Subtypes 68 selective kinase inhibitor 68 Combination Treatment 68 humanized monoclonal 68 Late Breaker 68 Receives Approvable Letter 68 Malignant Melanoma 68 J Pediatr 68 Peginterferon Alfa 2a 68 selective orally bioavailable 68 pan HDAC inhibitor 68 Fibrinogen 68 Circulating Tumor Cells 68 Hepatitis C Virus 68 Inflammatory Markers 68 Demonstrates Significant 68 Inflammatory Disease 68 itraconazole Sporanox 68 Prophylactic Treatment 68 Lung Cancer Drug 68 Parathyroid Hormone 68 Bacteremia 68 Eur J 68 Replacement Therapy 68 Improves Survival 68 Cannabinoid 68 Quantitation 68 Nicotine Vaccine 68 Immunotherapeutic 68 Curr Opin 68 Arch Neurol 68 Survival Benefit 68 #:#-# [020] 68 Gastric Cancer 68 AnaSpec Introduces 68 Selective Inhibitor 68 Respiratory Virus 68 Treated Patients 68 Initiates Clinical 68 imatinib Gleevec ® 68 ara C 68 Oral Mucositis 68 Pivotal Study 68 Oral Presentations 68 Epratuzumab 68 Doripenem 68 Severe Sepsis 68 antibody blinatumomab MT#/MEDI-# 68 Adefovir 68 Conjugate 68 FASEB J. 68 ceftazidime 68 Randomised Trial 67 Endometrial Cancer 67 Staphylococcal 67 Rheumatoid Arthritis Drug 67 Proves Effective 67 Potent Inhibitor 67 Dalbavancin 67 Phase IIb Clinical Trial 67 Phase III Trial 67 Mouse Models 67 Fulvestrant 67 Modulates 67 Mol Cell 67 Ann Oncol 67 Receptor Agonist 67 oral prodrug 67 Osteoporosis Treatment 67 Receptor Antagonist 67 Aliskiren 67 Immunol 67 Antiangiogenic 67 Autoimmune Diseases 67 Respiratory Syncytial Virus 67 Angiogenic 67 Lung Cancer Trial 67 Shows Efficacy 67 Demonstrates Positive 67 Cutaneous T 67 Aurora Kinase 67 Therapeutic Potential 67 Double Blind Randomized 67 Liver Tumors 67 Pivotal Phase III 67 Liposomal 67 NMDA Receptor 67 Disease Progression 67 LENALIDOMIDE 67 Dose Response 67 Anti Inflammatory Drug 67 Diabetic Nephropathy 67 Viral Infections 67 Tumor Targeting 67 Experimental Vaccine 67 Cholesterol Lowering Drug 67 Am J Clin 67 Randomized Study 67 Immunomedics Announces 67 Reductase 67 Breast Cancer Recurrence 67 Investigational Agent 67 Lymphocytic 67 Progenitor Cells 67 Improves Outcomes 67 Mg Usa 67 Proc Am Soc 67 platform HDL Mimetic 67 Vivo Efficacy 67 Genes Involved 67 Hepatitis C Infection 67 CYP#A# CYP#D# 67 non nucleoside inhibitor 67 Benign Prostatic Hyperplasia 67 torezolid 67 Daptomycin 67 Preclinical Evaluation 67 Atopic Dermatitis 67 Telbivudine 67 Systematic Review 67 tigecycline 67 J Clin Endocrinol Metab 67 Clinical Efficacy 67 Chronic Myeloid Leukemia 67 Hormone Receptor Positive 67 Patent Covering 67 Beneficial Effects 67 Monotherapy 67 Stent Restenosis 67 Hepatocellular 67 Novel Method 67 Thromb Haemost 67 Darinaparsin 67 Cancer Cells 67 Tumor Suppressor 67 #:#-# [023] 67 Recombinant Protein 67 Analogs 67 FDA Accepts 67 Is Well Tolerated 67 Suppl. 67 Clostridium difficile Infection 67 Systemic Sclerosis 67 Gene Mutation 67 Protein Kinase 67 Pegylated 67 Kidney Transplant Recipients 67 Poster Presentation 67 Appears Safe 67 Adenoma 67 Soy Isoflavones 67 #:#-# [031] 67 Pralatrexate 67 Induces 67 Tumor Growth 67 Alkaline Phosphatase 67 Cell Proliferation 67 Nanoemulsion 67 Controlled Study 67 Antigens 67 Macrolide 67 Cyclooxygenase 2 67 Molecular Diagnostic Test 67 Immunostimulatory 67 Anthrax Toxin 67 Immunomodulatory 67 Successfully Treated 67 Prognostic Significance 67 Adjuvant Therapy 67 J Am Soc 67 Dose Escalation 67 Nymox NX 67 Improved Survival 67 Delafloxacin 67 Hematological Cancers 66 Anti Inflammatory 66 Anticancer Agent 66 Anticoagulant 66 Receptor Antagonists 66 JAK2 Inhibitor 66 Lanthanum Carbonate 66 Valopicitabine 66 Highly Potent 66 Denufosol 66 Safinamide 66 Orthop Surg 66 Bacterial Infections 66 ECCMID 66 Int J Radiat Oncol 66 Synthase 66 Annu Rev 66 Protein Involved 66 Shown Effective 66 Randomized Double Blind 66 Refractory Hodgkin Lymphoma 66 Safety Tolerability 66 Randomized Double Blind Placebo 66 J Am Coll 66 Phase 1b Clinical Trial 66 Toxicol 66 siRNA Delivery 66 Phase Ib Clinical Trial 66 Sipuleucel T 66 Estrogen Receptor 66 Mylan Receives Approval 66 Novel Vaccine 66 solithromycin 66 Smooth Muscle 66 Soft Tissue Sarcoma 66 Maleate 66 Confirmatory Phase 66 Synthetic Peptide 66 Sustained Release 66 Clin Oncol 66 Antibiotic Resistant 66 Pharmacodynamics 66 Achieves Primary Endpoint 66 Endocrinol 66 Allergic Rhinitis 66 lexidronam injection 66 Commences Phase 66 Receives Milestone Payment 66 Advanced Prostate Cancer 66 Statistically Significant 66 Integrase Inhibitor 66 Patient Enrollment 66 Tipranavir 66 Placebo Controlled Study 66 FDA Approvals 66 Immunogenic 66 Patients Treated 66 Omacetaxine 66 Bazedoxifene 66 Protein Synthesis 66 HCV Genotype 66 Alfacell proprietary ribonuclease 66 Neoadjuvant Chemotherapy 66 Prostate Cancer Vaccine 66 Vaginal Gel 66 Escherichia coli Klebsiella pneumoniae 66 Brain Metastases 66 Dasatinib 66 Hematological Malignancies 66 Nephrol 66 Cytochrome P# 66 Transdermal Delivery 66 Neurol 66 Faropenem 66 Pivotal Phase 66 Proven Effective 66 Genetic Variation 66 Prospective Randomized Trial 66 Ann Rheum Dis 66 Prodrug 66 Autoimmune Disease 66 Peginterferon 66 Reports Preclinical Data 66 Biologic Therapy 66 Antifungals 66 Neurosurg 66 Therapeutic Targets 66 Carcinomas 66 Initiates Enrollment 66 Improve Survival 66 Develops Novel 66 Inhaled Corticosteroids 66 Integrase 66 Moxifloxacin 66 abacavir sulfate lamivudine 66 Initiates Clinical Trials 66 EMBO J. 66 Nat Rev 66 Genotypes 66 Haemophilus b Conjugate 66 BAL# [002] 66 Newly Diagnosed Multiple Myeloma 66 Treatment Naive Patients 66 Fluconazole 66 Study Showed 66 Polymorphism 66 Oral Cavity 66 #:#-# [006] 66 Humanized Anti 66 abstr 66 Vaccine Protects Against 66 Treatment Naïve Patients 66 Lupus Drug 66 Pharmacother 66 Randomized Double blind 66 Phase IIa Clinical Trial 66 Epitope 66 Novel Compound 66 Diagnostic Tests 66 Bladder Cancer 66 Investigational Treatment 66 Myelofibrosis 66 Tumor Cells 66 PRN FDA Approves 66 HER2 Positive Breast Cancer 66 Free Full Text 66 Test Detects 66 Treatment Experienced 66 TRAIL R2 66 Lowers Risk 66 Interferon Alpha 66 Sirolimus Eluting 66 Interferon alfa 66 FDA Okays 66 dasatinib Sprycel ® 66 Demonstrated Significant 66 Collaborators Present 66 K. pneumoniae 66 J Am Acad 66 Innate Immunity 66 DNA Methylation 66 RNA Interference 66 PEGylated Fab fragment 66 Advanced Colorectal Cancer 66 Preclinical Efficacy 66 Successfully Completes Phase 66 Long Term Efficacy 66 Hypertensive Patients 66 Randomized Phase II 66 Temsirolimus 66 Develop Novel 66 Breast Tumors 66 erlotinib Tarceva ® 66 Vicriviroc 66 Therapeutic Efficacy 66 Metastatic Colorectal Cancer 65 Fast Track Status 65 Environ Health Perspect 65 Plasmid DNA 65 Preclinical Testing 65 SPRYCEL ® 65 Fluorouracil 65 Aggressive Prostate Cancer 65 Medoxomil 65 Drug Combo 65 Transcriptome 65 NDA Submission 65 Endothelial Cells 65 bactericidal activity 65 Regimens 65 Lenalidomide 65 novel VDA molecule 65 Multicenter Trial 65 Antiviral 65 Metastatic Renal Cell Carcinoma 65 Holds Promise 65 Cytotoxic T 65 Viral Suppression 65 Therapeutic Antibody 65 Diabetic Neuropathy 65 Tumor Angiogenesis 65 Dermatol 65 Fixed Dose 65 Bortezomib 65 Capecitabine 65 Allogeneic 65 Demonstrates Sustained 65 Dengue Virus 65 Mutagenesis 65 RNAi Therapeutics 65 PROSTASCINT R 65 Murine Model 65 Myeloid 65 targeting CD# 65 Cell Lymphoma 65 Slow Progression 65 Randomized Trials 65 Anticancer Compound 65 Kidney Transplant Patients 65 Radezolid 65 Enterococcus faecium 65 Arch Dermatol 65 Generic Version 65 Castration Resistant Prostate Cancer 65 Insulin Glargine 65 pneumoniae PRSP 65 Sapacitabine 65 Genotyping Test 65 Ultrasensitive 65 Cardiol 65 Immune Mediated 65 TB Vaccine 65 Immunosuppression 65 Pediatric Patients 65 Dendritic Cell 65 Lung Cancer Survival 65 Oral Anticoagulant 65 Tumor Progression 65 #:#-# [001] 65 Gram Negative 65 Prospective Randomized 65 Gout Drug 65 Kidney Function 65 Bone Metastases 65 Sangamo BioSciences Announces 65 Receives Orphan Drug 65 TNF Alpha 65 includes S. anginosus 65 Multicenter Phase 65 Int J Obes Relat 65 CYT# potent vascular disrupting 65 #-# Full Text 65 HCV Infection 65 Immune Cells 65 Macrolides 65 Drug Fails 65 Ecallantide 65 Cethromycin 65 Myelodysplastic Syndrome MDS 65 Am J Obstet 65 Susceptibility Testing 65 Metastatic Prostate Cancer 65 Migraine Drug 65 Anti Angiogenic 65 Antisense Drug 65 Submits IND 65 Lupus Nephritis 65 Targeted Therapy 65 Stakeholder Opinions 65 Cancer Incidence Mortality 65 Newly Diagnosed 65 Phase III Trials 65 Shows Promise 65 Oral Formulation 65 Streptococcus Pneumoniae 65 J Biol Chem 65 essential thrombocythemia ET 65 Chemotherapeutic Agents 65 Fondaparinux 65 Naive Patients 65 #:#-# [035] 65 Antiviral Drugs 65 Therapeutic Antibodies 65 Atypical Hemolytic Uremic Syndrome 65 Eur J Cancer 65 Mycophenolate Mofetil 65 Tyrosine Kinase 65 Am J Respir 65 Fidaxomicin 65 Files Investigational 65 Phase III Clinical Trials 65 Wound Dressing 65 Relapsing Remitting Multiple Sclerosis 65 Neutralizing Antibodies 65 Transcription Factor 65 Bavituximab 65 oral JAK1 65 Topline Results 65 Significantly Improves 65 Interferon Alfa 65 Breast Cancer Metastasis 65 Initiates Phase III 65 Begins Dosing 65 Endocrinol Metab 65 Virologic 65 Clinical Trial Data 65 Erlotinib 65 Acute Ischemic Stroke 65 Pafuramidine 65 Albuferon TM 65 Study Demonstrates 65 Prostate Tumors 65 sodium glucose cotransporter 65 broad spectrum cephalosporin 65 linezolid resistant 65 Vancomycin resistant 65 Initiates Dosing 65 Dose Finding 65 NS#/#A protease 65 Therapeutic Competitors Report 65 Antibody Drug Conjugate 65 Leukemias 65 Shows Statistically Significant 65 Therapeutic Competitors Companies 65 complement inhibitor eculizumab 65 Autoantibodies 65 murine model 65 Cytotoxic 65 Genes Predict 65 EGFR HER2 65 Randomized Clinical Trial 65 Taxane 65 Streptococcus agalactiae 65 Enoxaparin 65 Significantly Improved 65 Malaria Vaccine 65 Peripheral Blood 65 Tesamorelin 65 Syndr 65 Haemophilus influenzae Moraxella catarrhalis 65 Tesetaxel 65 Anidulafungin 65 Itraconazole 65 Malignancies 65 Universal Flu Vaccine 65 Begin Clinical Trials 65 Slows Progression 65 Antiplatelet 65 Intravenous Human 65 Randomized Comparison 65 glycopeptide 65 Abstract Full Text 65 Poster Presentations 65 Maribavir 65 delafloxacin 65 Granulocyte Colony Stimulating Factor 65 Telaprevir VX 65 Prove Effective 65 #:#-# [037] 65 Antisense Oligonucleotides 65 Biomarker Study 65 Announces Poster Presentations 65 familial amyloidotic polyneuropathy FAP 65 Contrast Agents 65 Renal Cancer 65 Postmenopausal Women 65 Patients Receiving 65 Epitopes 65 Treatment Reduces 65 Voreloxin 65 recombinant subunit vaccine 65 Protein Function 64 Treatment Shows Promise 64 Cerebrospinal Fluid 64 Dose Escalation Study 64 Oligonucleotides 64 Initiate Phase III 64 MEK Inhibitor 64 Solid Tumors 64 Aflibercept 64 radezolid 64 Avian Flu Vaccine 64 Prognostic Value 64 Cell Adhesion 64 J Clin Oncol 64 Stomach Cancer 64 Leukemia Cells 64 Bucindolol 64 Selective Cardiac Myosin 64 Arthritis Drug 64 Disease Modifying 64 Entry Inhibitor 64 Dehydrogenase 64 Cancer Therapies 64 AASLD Meeting 64 Ophthalmol 64 Janus Kinase 64 Hemodialysis Patients 64 Proteasome 64 Nucleic Acids Res 64 Postdoctoral Position 64 Subunit 64 Heart Circ Physiol 64 Am J Epidemiol 64 Psoriasis Drug 64 Chemoradiation 64 Randomized Controlled Trials 64 doi #.#/fj.#-# 64 Seasonal Influenza 64 Prostatic 64 Collaborators Publish 64 Controlled Clinical Trial 64 Demonstrates Potential 64 orally administered inhibitor 64 Receives Fast Track 64 selective inhibition 64 MDRSP 64 Tumor Necrosis Factor 64 Treatment Regimens 64 Chronic Sinusitis 64 Efficacious 64 Critically Ill Patients 64 investigational antibiotic 64 Glatiramer Acetate 64 investigational humanized monoclonal antibody 64 Receives FDA Clearance 64 Decitabine 64 evaluating tivozanib 64 Soriatane R 64 Suppresses 64 Advanced Solid Tumors 64 #th Interscience Conference 64 Retroviral 64 Mg Uk 64 J Natl Cancer Inst 64 Glufosfamide 64 Teva Provides Update 64 Non Invasive Treatment 64 Chronic Lymphocytic Leukemia CLL 64 Pathol 64 CrossRef Medline 64 Palifosfamide 64 Bacterial Infection 64 Initiates Phase 64 Autoimmune Disorders 64 Histone 64 Clin Chem 64 Commonly Used 64 Granted Orphan Drug 64 Poliovirus 64 Tolerability 64 B Cell Lymphoma 64 PKC# 64 TM PCA3 64 Protein Biomarkers 64 Autologous Stem Cell Transplantation 64 Prognostic Factors 64 Cholesterol Lowering 64 Hepatic Encephalopathy 64 investigational oral inhibitor 64 Predict Response 64 RON Notch 64 Myeloma Patients 64 Multicenter Randomized 64 Piperacillin 64 Advanced Pancreatic Cancer 64 Reverse Transcriptase 64 Secretion 64 Molecular Mechanism 64 DNA intercalator 64 Conjugates 64 FOLOTYN ® 64 Patients Undergoing 64 J Acquir Immune Defic 64 Analytical Tool 64 Romidepsin 64 Subtype 64 Deforolimus 64 proteasome inhibitor 64 Confirms Efficacy 64 fosbretabulin 64 Cardiovascular Events 64 Anti CD# Antibody 64 Carotid Stenting 64 Study Shows Benefits 64 Adjuvanted 64 Epilepsy Drug 64 Personalized Immunotherapy 64 Magnetic Nanoparticles 64 Intracranial Aneurysms 64 #:#-# [033] 64 Gets FDA Clearance 64 Pandemic Flu Vaccine 64 Dry Powder Inhalers 64 Mutational 64 PRTX 64 PI3 64 Combination Vaccine 64 Infect Dis 64 Mutation Detection 64 TNF Blockers 64 Pediatr 64 protein tyrosine phosphatase 1B 64 Carfilzomib 64 Adjunctive Therapy 64 histone deacetylase HDAC inhibitor 64 Rheumatoid Arthritis Patients 64 AAG geldanamycin analog 64 Plaque Psoriasis 64 Prostate Cancer Progression 64 Newly Identified 64 DiLA2 64 novel orally bioavailable 64 Sustained Efficacy 64 VentiRx Pharmaceuticals 64 selective agonist 64 antibody MAb 64 Molecular Basis 64 Cytomegalovirus CMV 64 Commence Phase 64 Janus kinase 64 Melphalan 64 polymerase inhibitor 64 Mantle Cell Lymphoma 64 Initiated Phase 64 Lubiprostone 64 liposomal amphotericin B 64 Emerging Therapies 64 Telithromycin 64 Molecular Diagnostic 64 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 64 Obstet Gynecol 64 Combo Therapy 64 Neoplasms 64 Recurrent Breast Cancer 64 Drug Resistant Bacteria 64 Aplidin R 64 Targeted Therapies 64 monoclonal antibody conjugated 64 Parainfluenza 64 methicillin susceptible Staphylococcus aureus 64 Viral Load 64 Am J Pathol 64 Pegylated Liposomal Doxorubicin 64 Ovarian Cancers 64 Pemphigus Vulgaris 64 initiated Phase Ib 64 Secondary Hyperparathyroidism 64 Smallpox Vaccine 64 Int J 64 Induces Apoptosis 64 Breast Cancers 64 Cilostazol 64 Pathogenesis 64 Milestone Payment 64 Investigational Oral 64 Radical Prostatectomy 64 #:#-# [029] 64 FDA APPROVES 64 Clinical Trial Evaluating 64 Gene Expression Analysis 64 Percutaneous Tibial Nerve Stimulation 64 Gastrointestinal Stromal Tumors 64 Ziprasidone 64 vapreotide acetate 64 Drug Formulation 64 Hepatitis C Genotype 64 Elderly Patients 64 Pre Cancerous 64 Vaccine Shows Promise 64 Beta Amyloid 64 ALN HPN 64 Announcement acc 64 Protein Biomarker 64 Microbiol 64 Gene Variant 64 Rigel R# 64 Oral Interferon 64 Bevacizumab 64 Tablet Formulation 64 Brentuximab Vedotin SGN 64 Radiation Induced 64 HER1 64 Phenotypes 64 Reduces Risk 64 Bruton tyrosine kinase 64 Phys Ther 64 Nebulized 64 Signaling Pathway 64 Announces FDA Clearance 64 Hepatitis B Vaccine 63 Chronic Inflammation 63 Idiopathic Pulmonary Fibrosis 63 Diffuse Large B 63 Significantly Reduces 63 Guidelines Recommend 63 Treatment Resistant 63 Clinical Study Shows 63 Klebsiella pneumonia 63 Posaconazole 63 Osteoporosis Drug 63 Romiplostim 63 Multidrug Resistant 63 ergot derivatives 63 Cell Biol 63 Initiates Phase 2b 63 cyclin dependent kinase inhibitor 63 Non Inferiority 63 Skeletal Muscle 63 nucleoside analog 63 Retrovirus 63 Gene Variants 63 Highly Pathogenic 63 Prenatal Diagnosis 63 Drug Eluting 63 Antiplatelet Therapy 63 agonistic human 63 Vitro Diagnostic 63 Localized Prostate Cancer 63 Follicular Lymphoma 63 highly selective inhibitor 63 Proc Natl Acad Sci 63 Dapagliflozin 63 Superoxide 63 Completes Dosing 63 Cervical Dysplasia 63 Nephrol Dial Transplant 63 Macrophage 63 J Child Adolesc 63 developing Bicifadine serotonin 63 NS5b 63 Staphylococcus epidermidis 63 Thromboembolic 63 Inhalation Solution 63 Upregulation 63 topical gel formulation 63 Inhaled Liposomal Ciprofloxacin 63 Metabolic Disease 63 Medullary Thyroid Cancer 63 HCV polymerase 63 Bicalutamide 63 Antiarrhythmic 63 Liver Injury 63 First Patient Treated 63 Novel Treatments 63 Cyclosporine 63 Virulence 63 Potentially Fatal 63 Immunoassays 63 GW# [003]